Match Group Inc vs GeneDx Holdings Corp — how do they compare? Match Group Inc trades at $36.82 (market cap $8.43B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Match Group Inc is far larger — about 3.6× GeneDx Holdings Corp's market cap, and Match Group Inc pays a 2.18% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MTCH | WGS | |
|---|---|---|
Market Cap | $8.43B | $2.32B |
Sector | Media | Technology |
52-Week High | $41.24 | $167.51 |
52-Week Low | $28.90 | $34.51 |
Enterprise Value | $11.40B | $2.35B |
Dividend Yield | 2.18% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Trailing returns across standard periods
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →